Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks

G. Bussone, G. C. Manzoni, P. Cortelli, M. Roncolato, L. Fabbri, C. Benassuti

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This cross-over, double blind, randomized, multi-centre study evaluated the consistency of efficacy and safety of oral sumatriptan in 233 migraneurs. The patients received 50 mg oral sumatriptan or placebo for the treatment of 12 migraine attacks. Within each group of 4 attacks, three were treated with sumatriptan and one with placebo, according to a randomization list. Over all the attacks, the efficacy rate was statistically significant for sumatriptan against placebo at 2 or 4 hours (2 hours: sumatriptan 60%, PLO 38%, p

Original languageEnglish
Pages (from-to)272-278
Number of pages7
JournalNeurological Sciences
Volume21
Issue number5
DOIs
Publication statusPublished - Oct 2000

Fingerprint

Sumatriptan
Migraine Disorders
Placebos
Therapeutics
Random Allocation
Safety

Keywords

  • Efficacy
  • Migraine
  • Safety
  • Sumatriptan

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks. / Bussone, G.; Manzoni, G. C.; Cortelli, P.; Roncolato, M.; Fabbri, L.; Benassuti, C.

In: Neurological Sciences, Vol. 21, No. 5, 10.2000, p. 272-278.

Research output: Contribution to journalArticle

Bussone, G, Manzoni, GC, Cortelli, P, Roncolato, M, Fabbri, L & Benassuti, C 2000, 'Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks', Neurological Sciences, vol. 21, no. 5, pp. 272-278. https://doi.org/10.1007/s100720070064
Bussone, G. ; Manzoni, G. C. ; Cortelli, P. ; Roncolato, M. ; Fabbri, L. ; Benassuti, C. / Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks. In: Neurological Sciences. 2000 ; Vol. 21, No. 5. pp. 272-278.
@article{e0d441ae9d6142f39a5d24b7a580d082,
title = "Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks",
abstract = "This cross-over, double blind, randomized, multi-centre study evaluated the consistency of efficacy and safety of oral sumatriptan in 233 migraneurs. The patients received 50 mg oral sumatriptan or placebo for the treatment of 12 migraine attacks. Within each group of 4 attacks, three were treated with sumatriptan and one with placebo, according to a randomization list. Over all the attacks, the efficacy rate was statistically significant for sumatriptan against placebo at 2 or 4 hours (2 hours: sumatriptan 60{\%}, PLO 38{\%}, p",
keywords = "Efficacy, Migraine, Safety, Sumatriptan",
author = "G. Bussone and Manzoni, {G. C.} and P. Cortelli and M. Roncolato and L. Fabbri and C. Benassuti",
year = "2000",
month = "10",
doi = "10.1007/s100720070064",
language = "English",
volume = "21",
pages = "272--278",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "5",

}

TY - JOUR

T1 - Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks

AU - Bussone, G.

AU - Manzoni, G. C.

AU - Cortelli, P.

AU - Roncolato, M.

AU - Fabbri, L.

AU - Benassuti, C.

PY - 2000/10

Y1 - 2000/10

N2 - This cross-over, double blind, randomized, multi-centre study evaluated the consistency of efficacy and safety of oral sumatriptan in 233 migraneurs. The patients received 50 mg oral sumatriptan or placebo for the treatment of 12 migraine attacks. Within each group of 4 attacks, three were treated with sumatriptan and one with placebo, according to a randomization list. Over all the attacks, the efficacy rate was statistically significant for sumatriptan against placebo at 2 or 4 hours (2 hours: sumatriptan 60%, PLO 38%, p

AB - This cross-over, double blind, randomized, multi-centre study evaluated the consistency of efficacy and safety of oral sumatriptan in 233 migraneurs. The patients received 50 mg oral sumatriptan or placebo for the treatment of 12 migraine attacks. Within each group of 4 attacks, three were treated with sumatriptan and one with placebo, according to a randomization list. Over all the attacks, the efficacy rate was statistically significant for sumatriptan against placebo at 2 or 4 hours (2 hours: sumatriptan 60%, PLO 38%, p

KW - Efficacy

KW - Migraine

KW - Safety

KW - Sumatriptan

UR - http://www.scopus.com/inward/record.url?scp=0034460718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034460718&partnerID=8YFLogxK

U2 - 10.1007/s100720070064

DO - 10.1007/s100720070064

M3 - Article

VL - 21

SP - 272

EP - 278

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 5

ER -